PARIS, July 2 /PRNewswire/ --Sanofi-aventis announced today that the FDA has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Accelerate business intelligence with searchable pipeline and business data for the world’s pharmaceutical and biotech companies.
eKnowledegBase can help you streamline your research activities and improve access to data.
Request a trial here.
PENZBERG, Germany--(BUSINESS WIRE)--Jul 2, 2009 - The Roche NimbleGen Sequence Capture Array and Roche`s xCELLigence RTCA Instrument are among the ten most innovative products in the 2008 Top Ten Innovative Product Award in China.
PENZBERG, Germany--(BUSINESS WIRE)--Jul 2, 2009 - The Roche NimbleGen Sequence Capture Array and Roche`s xCELLigence RTCA Instrument are among the ten most innovative products in the 2008 Top Ten Innovative Product Award in China.
PENZBERG, Germany--(BUSINESS WIRE)--Jul 2, 2009 - The Roche NimbleGen Sequence Capture Array and Roche`s xCELLigence RTCA Instrument are among the ten most innovative products in the 2008 Top Ten Innovative Product Award in China.
